Journal article
Prenatal Stress and Maternal Immune Dysregulation in Autism Spectrum Disorders: Potential Points for Intervention
Current pharmaceutical design, Vol.25(41), pp.4331-4343
01/08/2020
DOI: 10.2174/1381612825666191119093335
PMCID: PMC7100710
PMID: 31742491
Abstract
Background: Genetics is a major etiological contributor to autism spectrum disorder (ASD). Environmental factors, however, also appear to contribute. ASD pathophysiology due to gene x environment is also beginning to be explored. One reason to focus on environmental factors is that they may allow opportunities for intervention or prevention. Methods And Results: Herein, we review two such factors that have been associated with a significant proportion of ASD risk, prenatal stress exposure and maternal immune dysregulation. Maternal stress susceptibility appears to interact with prenatal stress exposure to affect offspring neurodevelopment. We also explore how maternal stress may interact with the microbiome in the neurodevelopmental setting. Additionally, understanding of the impact of maternal immune dysfunction on ASD has recently been advanced by recognition of specific fetal brain proteins targeted by maternal autoantibodies, and identification of unique mid-gestational maternal immune profiles. This might also be interrelated with maternal stress exposure. Animal models have been developed to explore pathophysiology targeting each of these factors. Conclusions: We are beginning to understand the behavioral, pharmacopathological, and epigenetic effects related to these interactions, and we are beginning to explore potential mitigating factors. Continued growth in understanding of these mechanisms may ultimately allow for the identification of multiple potential targets for prevention or intervention for this subset of environmental-associated ASD cases.
Details
- Title: Subtitle
- Prenatal Stress and Maternal Immune Dysregulation in Autism Spectrum Disorders: Potential Points for Intervention
- Creators
- David Q Beversdorf - Departments of Radiology, Neurology, and Psychological Sciences, and The Thompson Center for Neurodevelopmental Disorders, William and Nancy Thompson Endowed Chair in Radiology, University of Missouri, Columbia, MO, United StatesHanna E Stevens - Departments of Psychiatry and Pediatrics, Iowa Neuroscience Institute, University of Iowa, Iowa City, United StatesKara Gross Margolis - Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Morgan Stanley Children’s Hospital, Columbia University Medical Center, New York, United StatesJudy Van de Water - Department of Internal Medicine, Division of Rheumatology, Allergy, and Clinical Immunology, And the MIND Institute, University of California, Davis, CA, United States
- Resource Type
- Journal article
- Publication Details
- Current pharmaceutical design, Vol.25(41), pp.4331-4343
- DOI
- 10.2174/1381612825666191119093335
- PMID
- 31742491
- PMCID
- PMC7100710
- NLM abbreviation
- Curr Pharm Des
- ISSN
- 1381-6128
- eISSN
- 1873-4286
- Grant note
- DOI: 10.13039/100000002, name: National Institutes of Health, award: R42MH111347; DOI: 10.13039/100000102, name: Autism Treatment Network, award: UA3MC11054; DOI: 10.13039/100000005, name: Department of Defense, award: AR150091
- Language
- English
- Date published
- 01/08/2020
- Academic Unit
- Psychiatry; Stead Family Department of Pediatrics; Iowa Neuroscience Institute
- Record Identifier
- 9984070811802771
Metrics
21 Record Views